{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:01:49Z","timestamp":1788454909420,"version":"build-2803163510"},"reference-count":33,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T00:00:00Z","timestamp":1622246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Global polio eradication requires both safe and effective vaccines, and safe production processes. Sabin oral poliomyelitis vaccine (OPV) strains can evolve to virulent viruses and result in poliomyelitis outbreaks, and conventional inactivated poliomyelitis vaccine (Salk-IPV) production includes accumulation of large stocks of neurovirulent wild polioviruses. Therefore, IPV based on attenuated OPV strains seems a viable option. To increase the global supply of affordable inactivated vaccine in the still not-polio free world we developed an IPV made from the Sabin strains\u2013PoliovacSin. Clinical trials included participants 18\u201360 years of age. A phase I single-center, randomized, double-blind placebo-controlled clinical trial included 60 participants, who received one dose of PoliovacSin or Placebo. A phase II multicenter, randomized, double-blind, comparative clinical trial included 200 participants, who received one dose of PoliovacSin or Imovax Polio. All vaccinations were well tolerated, and PoliovacSin had a comparable safety profile to the Placebo or the reference Imovax Polio preparations. A significant increase in neutralizing antibody levels to polioviruses types 1\u20133 (Sabin and wild) was observed in PoliovacSin and Imovax Polio vaccinated groups. Therefore, clinical trials confirmed good tolerability, low reactogenicity, and high safety profile of the PoliovacSin and its pronounced immunogenic properties. The preparation was approved for clinical trials involving infants.<\/jats:p>","DOI":"10.3390\/vaccines9060565","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T03:45:29Z","timestamp":1622432729000},"page":"565","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Immunogenicity and Safety of Inactivated Sabin-Strain Polio Vaccine \u201cPoliovacSin\u201d: Clinical Trials Phase I and II"],"prefix":"10.3390","volume":"9","author":[{"given":"Anastasia","family":"Piniaeva","sequence":"first","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products RAS (FSBSI \u201cChumakov FSC R&D IBP RAS\u201d), 108819 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgy","family":"Ignatyev","sequence":"additional","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products RAS (FSBSI \u201cChumakov FSC R&D IBP RAS\u201d), 108819 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liubov","family":"Kozlovskaya","sequence":"additional","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products RAS (FSBSI \u201cChumakov FSC R&D IBP RAS\u201d), 108819 Moscow, Russia"},{"name":"Institute for Translational Medicine and Biotechnology, First Moscow State Medical University (Sechenov University), 117418 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yury","family":"Ivin","sequence":"additional","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products RAS (FSBSI \u201cChumakov FSC R&D IBP RAS\u201d), 108819 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Kovpak","sequence":"additional","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products RAS (FSBSI \u201cChumakov FSC R&D IBP RAS\u201d), 108819 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Ivanov","sequence":"additional","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products RAS (FSBSI \u201cChumakov FSC R&D IBP RAS\u201d), 108819 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5907-0615","authenticated-orcid":false,"given":"Anna","family":"Shishova","sequence":"additional","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products RAS (FSBSI \u201cChumakov FSC R&D IBP RAS\u201d), 108819 Moscow, Russia"},{"name":"Institute for Translational Medicine and Biotechnology, First Moscow State Medical University (Sechenov University), 117418 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliia","family":"Antonova","sequence":"additional","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products RAS (FSBSI \u201cChumakov FSC R&D IBP RAS\u201d), 108819 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Khapchaev","sequence":"additional","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products RAS (FSBSI \u201cChumakov FSC R&D IBP RAS\u201d), 108819 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Feldblium","sequence":"additional","affiliation":[{"name":"Perm State Medical University Named after Academician E.A. Wagner, 614990 Perm, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1784-4827","authenticated-orcid":false,"given":"Olga","family":"Ivanova","sequence":"additional","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products RAS (FSBSI \u201cChumakov FSC R&D IBP RAS\u201d), 108819 Moscow, Russia"},{"name":"Institute for Translational Medicine and Biotechnology, First Moscow State Medical University (Sechenov University), 117418 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Siniugina","sequence":"additional","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products RAS (FSBSI \u201cChumakov FSC R&D IBP RAS\u201d), 108819 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aydar","family":"Ishmukhametov","sequence":"additional","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products RAS (FSBSI \u201cChumakov FSC R&D IBP RAS\u201d), 108819 Moscow, Russia"},{"name":"Institute for Translational Medicine and Biotechnology, First Moscow State Medical University (Sechenov University), 117418 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1056\/NEJM199112193252504","article-title":"Ward and Ralph, H. Henderson. Strategies for the global eradication of poliomyelitis by the year 2000","volume":"325","author":"Peter","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/rmv.401","article-title":"Polio eradication: The OPV paradox","volume":"13","author":"Dowdle","year":"2003","journal-title":"Med. Virol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/infdis\/jiu295","article-title":"Vaccine-Derived Polioviruses","volume":"210","author":"Burns","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_4","unstructured":"Plotkin, S.A., Orenstein, W.A., Offit, P.A., and Edwards, K.M. (2018). Poliovirus vaccine\u2014Live. Vaccines, Elsevier. [7th ed.]."},{"key":"ref_5","unstructured":"World Health Organization (WHO) (2001). Transmission of wild poliovirus type 2\u2014Apparent global interruption. Wkly. Epidemiol. Rec., 76, 95\u201397."},{"key":"ref_6","unstructured":"World Health Organization (WHO) (2019). Report from the Twentieth Meeting of the Global Commission for Certification of Poliomyelitis Eradication, World Health Organization (WHO)."},{"key":"ref_7","unstructured":"Centers for Disease Control and Prevention (CDC) (1994). Certification of poliomyelitis eradication\u2014The Americas, 1994. MMWR Morb. Mortal Wkly. Rep., 43, 720\u2013722."},{"key":"ref_8","unstructured":"Centers for Disease Control and Prevention (CDC) (2001). Certification of poliomyelitis eradication\u2014The Western Pacific region, October 2000. MMWR Morb. Mortal Wkly. Rep., 50, 1\u20133."},{"key":"ref_9","unstructured":"Centers for Disease Control and Prevention (CDC) (2002). Certification of poliomyelitis eradication\u2014European Region, June 2002. MMWR Morb. Mortal Wkly. Rep., 51, 572\u2013574."},{"key":"ref_10","first-page":"941","article-title":"Polio-free certification and lessons learned\u2014South-East Asia","volume":"63","author":"Bahl","year":"2014","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1473-3099(15)00488-0","article-title":"Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: A comparative, observer-blind, randomised, controlled trial","volume":"16","author":"Clemens","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_12","unstructured":"(2021, May 18). Available online: https:\/\/www.who.int\/news\/item\/25-08-2020-global-polio-eradication-initiative-applauds-who-african-region-for-wild-polio-free-certification."},{"key":"ref_13","unstructured":"(2021, May 18). Available online: https:\/\/polioeradication.org\/wp-content\/uploads\/2021\/05\/weekly-polio-analyses-WPV-20210518.pdf."},{"key":"ref_14","unstructured":"(2021, May 18). Available online: https:\/\/polioeradication.org\/wp-content\/uploads\/2021\/05\/weekly-polio-analyses-cVDPV-20210518.pdf."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"20706","DOI":"10.2807\/1560-7917.ES2014.19.7.20706","article-title":"The 2010 outbreak of poliomyelitis in Tajikistan: Epidemiology and lessons learnt","volume":"19","author":"Yakovenko","year":"2014","journal-title":"Eurosurveillance"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5455","DOI":"10.1016\/j.vaccine.2017.03.038","article-title":"Characterization of human monoclonal antibodies that neutralize multiple poliovirus serotypes","volume":"35","author":"Puligedda","year":"2017","journal-title":"Vaccine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/bit.22788","article-title":"Multivariate Data Analysis on Historical IPV Production Data for Better Process Understanding and Future Improvements","volume":"107","author":"Thomassen","year":"2010","journal-title":"Biotechnol. Bioeng."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/bit.24798","article-title":"Scale-Down of the Inactivated Polio Vaccine Production Process","volume":"110","author":"Thomassen","year":"2013","journal-title":"Biotechnol. Bioeng."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6611","DOI":"10.1016\/j.vaccine.2015.10.091","article-title":"Production of high titer attenuated poliovirus strains on the serum-free PER.C6(\u00ae) cell culture platform for the generation of safe and affordable next generation IPV","volume":"33","author":"Sanders","year":"2015","journal-title":"Vaccine"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1586\/erv.11.51","article-title":"Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains","volume":"10","author":"Verdijk","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e02287-18","DOI":"10.1128\/mBio.02287-18","article-title":"Development of Thermostable Lyophilized Sabin Inactivated Poliovirus Vaccine","volume":"9","author":"Shin","year":"2018","journal-title":"Mbio"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.biologicals.2016.08.005","article-title":"Development of inactivated poliovirus vaccine from Sabin strains: A progress report","volume":"44","author":"Okayasu","year":"2016","journal-title":"Biologicals"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1016\/j.xphs.2020.12.012","article-title":"Physicochemical Characterization of Sabin Inactivated Poliovirus Vaccine for Process Development","volume":"110","author":"Torisu","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1080\/21645515.2019.1572408","article-title":"Surveillance of immunity acquired from poliovirus immunization including vaccination with the Sabin strain-derived inactivated vaccine","volume":"15","author":"Hotta","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_25","first-page":"39","article-title":"An ELISA system based on the specific class Y (IgY) antibodies from egg yolks for the quantitative determination of D-antigen in inactivated poliovirus vaccines","volume":"59","author":"Ivanov","year":"2014","journal-title":"Vopr. Virususologii"},{"key":"ref_26","unstructured":"World Health Organization (WHO) (1997). Manual for Virological Investigation of Poliomyelitis, WHO. WHO\/EPI\/GEN\/97.1."},{"key":"ref_27","unstructured":"UNICEF (2019). Inactivated Polio Vaccine (IPV): Supply Update, WHO."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1093\/cid\/cix116","article-title":"Next Generation Inactivated Poliovirus Vaccine: The Future Has Arrived","volume":"64","author":"Sutter","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.vaccine.2021.01.027","article-title":"Immunogenicity and safety of the inactivated poliomyelitis vaccine made from Sabin strains in a phase IV clinical trial for the vaccination of a large population","volume":"39","author":"Jiang","year":"2021","journal-title":"Vaccine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.vaccine.2014.11.015","article-title":"Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan","volume":"34","author":"Shimizu","year":"2016","journal-title":"Vaccine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/cid\/cix110","article-title":"Immune Serum from Sabin Inactivated Poliovirus Vaccine Immunization Neutralizes Multiple Individual Wild and Vaccine-Derived Polioviruses","volume":"64","author":"Sun","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.18821\/0507-4088-2016-61-1-9-15","article-title":"Vaccine-associated paralytic poliomyelitis in Russian Federation during the period of changes in vaccination schedule (2006\u20132013 yy.)","volume":"61","author":"Ivanova","year":"2016","journal-title":"Vopr. Virusol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"59","DOI":"10.31631\/2073-3046-2016-15-4-59-64","article-title":"Experimental Approaches to the Development of Inactivated Poliovirus Vaccine Based on Sabin Strains","volume":"15","author":"Ivanov","year":"2016","journal-title":"Epidemiol. Vaccinal Prev."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/6\/565\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:08:50Z","timestamp":1760162930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/6\/565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,29]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["vaccines9060565"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9060565","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,29]]}}}